The sum was factored into the company’s sales and earnings outlook for the year, he said. Meanwhile, Pfizer expanded its ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...

Pfizer maintained its 2025 guidance but noted it does not include any impact of tariffs or trade policy, “which we are unable to predict at this time.” ...

Pfizer (NYSE:PFE) is one of the world’s largest pharmaceutical companies, but at $22.59 per share as of this writing, the ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it can ...

Pfizer said today it would generate $1.7 billion more in savings from cost-cutting to its manufacturing and research operations and reported lower first-quarter revenue due to declining sales of its ...

Pfizer Q1 EPS beat at $0.92 vs. $0.67 estimate, but sales dipped 8% YoY to $13.71 billion, below $13.95 billion forecast. Paxlovid sales plunged 75%, while Vyndaqel jumped 33% and Comirnaty rose ...

Pfizer on Tuesday expanded its cost-cutting efforts and reported first-quarter profit that topped estimates, even as the company's sales fell, largely due to dwindling revenue for its antiviral ...

Pfizer on Tuesday reaffirmed its outlook for ... The company launched its multiyear cost-cutting plan in 2023 after the drugmaker miscalculated demand for its Covid-19 products.